Navigation Links
Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
Date:8/30/2013

MINNEAPOLIS/ST. PAUL (08/30/2013) A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).

The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).

The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found "online first" in the journal Antiviral Chemistry & Chemotherapy.

"If you have a condition that requires you to take a medication everyday, as many patients with HIV do, you wouldn't want to have to take that medication via daily injection," said Steven Patterson, Ph.D., professor at the Center for Drug Design at the University of Minnesota. "This finding is a big step in demonstrating this treatment could be taken as a pill, similar to other HIV drugs, and is suitable for eventual clinical translation."

University of Minnesota researchers first announced decitabine and gemcitabine could potentially combine to treat HIV in research published in August 2010. The drug combination was shown to work by lethal mutagenesis that could obliterate HIV by causing the virus to mutate to a point where it was no longer infectious. For some patients, HIV's ability to quickly mutate and evolve can result in drug resistance. For patients who have developed resistance to currently available HIV treatments, the decitabine-gemcitabine drug combination could prove an effective alternative and secondary line of defense.

In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.

"There's still a lot of work that needs to be done to demonstrate the safety and efficacy of this drug combination before human clinical trials can begin," said Patterson. "But we're optimistic that we're moving forward."


'/>"/>

Contact: Miranda Taylor
tayl0551@umn.edu
612-626-2767
University of Minnesota Academic Health Center
Source:Eurekalert

Related biology news :

1. Keck award enables Carnegie Mellon and Stanford to dramatically expand crowdsourced RNA design
2. Report presents designs for study of cancer risks near US nuclear facilities
3. Research is ensuring stormwater systems are designed for the future
4. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
5. African scientist, designer partner to fashion anti-malaria garment that wards off bugs
6. Portable diagnostics designed to be shaken, not stirred
7. MIT-designed cooler preserves tuberculosis drugs, records doses
8. Progress in Osteoporosis re-launched with new design, now invites commentary
9. Faster, cheaper gas and liquid separation using custom designed and built mesoscopic structures
10. SACLA draws acclaim for unique XFEL design
11. A new type of data papers designed to publish online interactive keys identifying biodiversity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2016)... , Jan. 22, 2016 ... addition of the "Global Biometrics Market ... their offering. --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> Research and Markets ( ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized breaches ... to find new ways to ensure data security and ... iOS and Android that ties a ... transforming it into a hardware authorization token. Customer service ... their fingerprint on their KodeKey enabled device to verify ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ANNAPOLIS, Md. , Feb. 10, 2016  The ... E. Busch , has announced that University of Maryland ... MD, PhD, MBA and University of Maryland Medical System ... recipients of the "Speaker,s Medallion," the highest honor given ... House of Delegates. Dean Reece and ...
(Date:2/10/2016)... Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), ... and medical radioisotope applications for the treatment of prostate, ... announced its financial results for the second quarter and ... 2015. --> --> ... of fiscal 2016, which ended December 31, 2015, a ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a leading custom ... Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The ... for its annual event, which will run from 3:00 p.m. - 8:30 p.m. ...
(Date:2/10/2016)... ... 10, 2016 , ... Curoverse announced today that the open-source, ... capabilities for managing and processing genomic and health data at petabyte scale. ... and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. “Microsoft ...
Breaking Biology Technology: